Skip to NavigationSkip to content

sickle cell disease

Novartis' sickle cell drug reduces vaso-occlusive crises by 35% at Phase 2

Novartis has presented new Phase 2 data for its humanised anti-P-selectin monoclonal antibody crizanlizumab in the treatment of sickle cell disease (SCD). The findings were reported in the American Journal of Hematology.

The data, derived from a 52-week study of 137 patients showed that the drug reduced the number of patients experiencing vaso-occlusive crisis (VOC) by 35.8% compared to the 16.9% reduction in the placebo group.

FDA gives go-ahead to first sickle cell treatment in 20 years

Image: OpenStax College, Anatomy & Physiology

Emmaus Medical has been handed approval for the first new treatment for sickle cell disease in two decades. The active ingredient is the only major question mark over the drug, with L-glutamine being the primary ingredient in Endari and already cheaply available over-the-counter (OTC) in the US.

Shares in Global Blood jump after positive results for trial sickle cell drug

Global Blood Therapeutics (Nasdaq: GBT) shares jumped to close up over 9% Friday after the company said its trial drug to treat sickle cell disease boosted hemoglobin production in a small study.

Chief Executive Ted Love said: "Overall, the data collected to date in study GBT440-001 indicate that we have a drug candidate that we can move into a pivotal trial later this year.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches